Cardiovascular Events

Cardiovascular·MeSH: Coronary Artery Disease

16 drugs in development·11 companies·1 clinical trial

Drug Pipeline by Phase

Approved(16)

Drug	Company
amlodipine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
candesartan cilexetil	Aptinyx Inc. (APTX)
exforge hct	Novartis AG (NVS)
felodipine	Mylan II B.V. (MYL)
losartan	Mylan II B.V. (MYL)
losartan	Teva Pharmaceutical Industries Limited (TEVA)
nebivolol	ANI PHARMACEUTICALS INC (ANIP)
olmesartan medoxomil	Amneal Pharmaceuticals, Inc. (AMRX)
ozempic	Novo Nordisk A/S (NVO)
prasugrel	Mylan II B.V. (MYL)
spironolactone	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
telmisartan	Inventiva S.A. (IVA)
tirofiban	NEXUS BIOPHARMA INC (NEXS)
Trulicity	ELI LILLY & Co (LLY)
Trulicity®	ELI LILLY & Co (LLY)
valsartan	Mylan II B.V. (MYL)

BioSniper tracks 16 drugs in development for Cardiovascular Events across 11 companies.

There are 1 clinical trial targeting Cardiovascular Events tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.